BackgroundFasting blood glucose (FBG) variability, an emerging marker of glycemic control, has been shown to be related to the risk of cardiovascular events and all‐cause mortality in subjects with or without diabetes. However, whether FBG variability is independently associated with a higher all‐cause mortality in heart transplant recipients remains unknown.MethodsWe performed a retrospective cohort study including 373 adult recipients who survived for at least 1 year after heart transplantation with a functioning graft and measured FBG more than three times within first year after transplantation. Multivariable adjusted Cox regression analyses were performed to assess the association between FBG variability and all‐cause mortality.ResultsPatients were categorized into three groups according to the coefficient of variation of FBG level: ≤7.0%, 7.0%–13.5%, and >13.5%. During a median follow‐up of 44.4 months (interquartile range [IQR], 22.6–63.3 months), 31 (8.3%) participants died. In univariate analyses, FBG variability was associated with an increased all‐cause mortality (hazard ratio [HR]: 3.00, 95% confidence interval [CI]: 1.67, 5.38; p < .001). This association remained materially unchanged in the multivariable model adjusted for components of demographics, cardiovascular history and lifestyle, hospital information, immunosuppressive therapy, and post‐transplant renal function (HR: 2.75, 95% CI: 1.43, 5.28; p = .004).ConclusionsAfter heart transplantation, high FBG variability is strongly and independently associated with an increased risk of all‐cause mortality. Our findings suggest that FBG variability is a novel risk factor and prognostic marker for heart transplantation recipients in outpatient clinic.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.